Halozyme Therapeutics has signed a global partnership and licence agreement with Incyte to assess additional subcutaneous formulations of INCA033989, a monoclonal antibody targeting mutant calreticulin (mutCALR), in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs).
Takeda and the Indonesian Government have announced a multi-phased collaboration to strengthen the country’s plasma ecosystem and expand access to plasma-derived medicinal products (PDMPs).
The US Food and Drug Administration (FDA) has approved Viatris, a global healthcare company’s Iron Sucrose Injection for treating iron deficiency anaemia (IDA) in adults and children aged two and older with chronic kidney disease (CKD).
Roche Canada has received Health Canada’s authorisation for PiaSky (crovalimab for injection), to treat paroxysmal nocturnal haemoglobinuria (PNH).
The US Food and Drug Administration (FDA) has accepted and granted priority review to AstraZeneca's supplemental New Drug Application (sNDA) for Calquence (acalabrutinib) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
The Department of Health (DoH) Abu Dhabi in the UAE has entered into a memorandum of understanding (MoU) with Pfizer Gulf to bolster research in areas including sickle cell disease (SCD).
The US Food and Drug Administration (FDA) has granted orphan drug designation for clinical-stage biopharmaceutical company Disc Medicine’s investigational therapy, DISC-3405, for the treatment of polycythemia vera (PV).
Agios Pharmaceuticals has signed a license agreement with Alnylam Pharmaceuticals for preclinical Small interfering RNA (siRNA) development candidate to treat polycythemia vera (PV).
Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
The U.S. Food and Drug Administration (FDA) has granted efanesoctocog alfa – earlier termed BIVV001 (rFVIIIFc-VWF-XTEN) – Fast Track Designation (FTD) for the treatment of patients suffering from hemophilia A.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.